Novel therapeutics for the treatment of graft-versus-host disease

Expert Opinion on Investigational Drugs

Volumn 11, Issue 9, 2002, Pages 1271-1280

  Jacobsohn, David A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute; Bone marrow transplantation; Chronic; Graft versus host disease; Haematopoietic stem cell transplantation; Prophylaxis; Treatment

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BUSULFAN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETRETINATE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INOLIMOMAB; INTERLEUKIN 11; INTERLEUKIN 2 RECEPTOR ANTIBODY; KERATINOCYTE GROWTH FACTOR; LIPOPOLYSACCHARIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VISILIZUMAB;

BONE MARROW SUPPRESSION; CELLULAR IMMUNITY; CLINICAL FEATURE; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PUVA; REVIEW; SEDATION; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036738081     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.9.1271     Document Type: Review

References (81)

1. Pathophysiology and treatment of graft-versus-host disease
2. Acute and chronic graft-versus-host disease after allogeneic peripheral- blood stem-cell and bone marrow transplantation: A meta-analysis
3. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice
4. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers
5. Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line
6. Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells
7. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon
8. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms
9. Interaction of antigenic peptides with MHC and TCR molecules
10. Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules
11. Pathophysiologic mechanisms of acute graft-vs.-host disease
12. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease
13. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction
14. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro human skin explant model
15. Drug therapy for acute graft-versus-host disease prophylaxis
16. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
17. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
18. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial
19. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention
20. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
21. Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
22. Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction
23. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation
24. A Phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation
25. Mycophenolate mofetil
26. Mycophenolate mofetil in cadaveric renal transplantation
27. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin
28. CTLA-4 is a second receptor for the B cell activation antigen B7
29. Transplantation of anergic histoincompatible bone marrow allografts
30. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
31. Rapamune (Sirolimus, rapamycin): An overview and mechanism of action
32. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
33. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
34. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide
35. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation
36. Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens
37. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow
38. Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow
39. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Importance of a graft-versus-leukaemia effect
40. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation
41. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo
42. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection
43. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
44. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT)
45. Prednisone therapy for acute graft-versus-host disease: Short- versus long-term treatment. A prospective randomized trial
46. High dose bolus methylprednisolone for the treatment of acute graft versus host disease
47. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults
48. Early treatment of acute graft-versus-host disease with high- or low- dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation
49. Management of acute graft-versus-host disease
50. Poor outcome in steroid refractory GVHD with ATG treatment
51. A Phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease
52. A clinical Phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease
53. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter Phase III study
54. A Phase II/III randomized, double-blind, placebo-controlled multicenter trial of humanized anti-TAC for prevention of acute graft-versus-host disease (GVHD) in recepients of marrow transplantation from unrelated donors
55. A humanized antibody that binds to the interleukin 2 receptor
56. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders
57. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
58. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation
59. Pentostatin: A novel treatment for steroid refractory acute GVHD
60. T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density
61. Clonal deletion by a monoclonal antiblast antibody following primary mixed lymphocyte culture
62. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL
63. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro
64. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells
65. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
66. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease
67. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation
68. Thalidomide as salvage therapy for chronic graft-versus-host disease
69. Thalidomide for the treatment of chronic graft-versus-host disease
70. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
71. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
72. Pentostatin: A promising treatment for refractory chronic GVHD
73. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease
74. Treatment of chronic graft-versus-host disease with clofazimine
75. Hydroxychloroquine for the treatment of chronic graft-versus-host disease
76. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA)
77. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients
78. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease
79. 1994 Consensus Conference on Acute GVHD Grading
80. T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia
81. + immune regulatory cells inhibits graft-versus-host disease lethality